Abstract. Co-infection of human immunodeficiency virus and malaria is not uncommon in people living in sub-
HIV infection is an increasing health problem in subSaharan Africa where malaria is endemic, and these two diseases are serious threats to public health. 1, 2 Like malaria parasites, HIV is an intracellular pathogen. Malaria parasites reside in the hepatocytes as the pre-erythrocytic stages and then in the red blood cells as the erythrocytic stages, while HIV mostly attacks CD4 cells and macrophages. It is well appreciated that cell-mediated immunity (CMI) plays an important protective role against both HIV and acute malaria infections. 3, 4 Because HIV infections result in generalized immunosuppression by depleting CD4 + T lymphocytes, HIV/AIDS can have a broad impact on the ability of the immune system of HIV-infected patients to control opportunistic infections and other infectious diseases. Previous studies have demonstrated that malaria infection is exacerbated in HIV-positive patients. Whitworth et al reported that the level of parasitemia and clinical episodes due to malaria were significantly increased in HIV-positive adults patients in Uganda. 5 Another study in Uganda demonstrated that HIV-positive children had moresevere clinical outcomes than those who were HIV-negative. 6 In contrast, other studies have found no observable interaction between malaria and HIV infection. Studies in Kinshasa demonstrated that the clinical outcome of malaria was the same for both HIV-positive and HIV-negative children, and that there was no difference in malaria parasitemia between HIV-positive and HIV-negative children. 7, 8 Another study in Kigali demonstrated that malaria parasitemia in pregnant HIV-positive women was the same as in pregnant HIVnegative women. 9 Recent studies on patients in Malawi 10, 11 have reported increased HIV-1 viral load and reversible induction of HIV-1 replication in CD14 macrophages during acute malaria infection caused by Plasmodium falciparum. Based on the fact that healthy people living in malaria endemic areas who are exposed to repeated malaria infections can develop a partially protective non-sterilizing immunity against the infection, we hypothesized that a disruption of the immune system as commonly observed in HIV patients may result in quantitative and/or qualitative differences in antibody against malaria parasites, thus affecting the outcome of malaria infection. To investigate the possible interactions between HIV and malaria infections, 47 specimens from 25 HIV-discordant and -concordant couples (mean age 39; median age, 41; age range, 26-51) who had been selected during a pilot study in a large factory in Kinshasa in 1998 and who lived in P. falciparum malaria endemic areas were analyzed. The primary purpose of the study was to assess the HIV cytotoxic T lymphocytes response in both the HIV+ subject and the subject's HIV-partner. Lack of availability of flow cytometry facility in Kinshasa and poor viability of transported cells prevented a direct measurement of CD4 T cell count. What is known, however, is that these couples living in malaria endemic area had experienced numerous episodes of clinical malaria in their lifetimes. According to the national malaria control program of the DRC, nearly 44% of outpatients of all ages at representative hospitals in Kinshasa had a clinical diagnosis of malaria from 1997-1999. Moreover, the higher incidence of malaria in Kinshasa occurs from JuneJuly and December-January. The samples analyzed in our study were collected from May 1998 to January 1999 with an interruption from August to November because of war in Kinshasa. The studies reported here were approved by an ethics committee in the DRC and the Joint Committee on Clinical Investigation of Johns Hopkins University.
HIV viral load was estimated by determining HIV-1 RNA levels in the plasma by the reverse transcriptase-polymerase chain reaction method (Amplicor HIV-1 Monitor Assay, version 1.5, Roche Molecular Diagnostics, Branchburg, NJ). The level of sensitivity of the assay is 50 copies/mL. A standard enzyme-linked immunosorbent assay (ELISA) was used to measure antibodies recognizing antigens in asexual erythrocytic stage P. falciparum. 12 Cultured P. falciparum 13 (trophozoite and schizont stages, 3D7 strain) were lysed by sonication, and the supernatant obtained after centrifugation at 14,000 rpm (30 min, 4°C) was used to coat ELISA plates (1 g protein/well in bicarbonate buffer). After blocking with 5% non-fat milk, the plates were washed twice with phosphatebuffered saline-0.1% Tween 20 and incubated with various serial dilutions of plasma from the study participants and a pool of 10 North American normal human sera (negative controls) for one hour at 37°C. After further washing, 100 L/well of peroxidase-conjugated goat anti-human IgM and IgG antibodies diluted in blocking solution (1:500) was added, and the plates incubated for one hour at 37°. After a final wash, 100 L/well of chromogen containing substrate (ABTS) mixture was added, and reactions were stopped after 45 minutes. Optical densities were measured using a plate reader at 450 nm.
Anti-P. falciparum antibodies and HIV status. To investigate the relationship between malaria and HIV, malaria antibody titers were compared in 23 HIV-positive (12 female) and 24 HIV-negative individuals (14 male). A 2 analysis showed no correlation between antibodies against malaria parasite and HIV status (P ‫ס‬ 0.370). Table 1 Table 2 summarizes the results of various statistical analyses performed. No correlation was observed among the test parameters used for comparison. Further investigation did not find any significant relationship between gender and other parameters used in the study: HIV status (P ‫ס‬ 0.876), viral load (P ‫ס‬ 0.412), malaria antibody titer (P ‫ס‬ 0.141), and malaria ELISA (P ‫ס‬ 0.319).
P. falciparum growth inhibition. We then considered the possibility that similar concentrations of antibodies are produced in individuals regardless of HIV status but that they might differ with respect to antigen specificity and/or in their ability to inhibit parasite growth in the erythrocytes. To identify specific proteins recognized by various plasma samples, asexual cultures (3D7 parasites) were treated with 0.15% saponin and parasite proteins fractionated by SDS polyacrylamide gel electrophoresis 12% gel and transferred to nitrocellulose membrane for immunoblot analysis. Fifteen DRC plasma specimens (1:500 dilution) were used as the primary antibody and peroxidase-conjugated goat antihuman IgG (1: 5,000 dilution) as the secondary antibody with one hour of incubation for each step at room temperature. Membranes were washed four times between incubations with the primary and secondary antibodies, and detection was done using the ECL kit (Amersham Biosciences, Buckinghamshire). Among the 15 plasma specimens, six were HIV-positive and malaria antibody-positive, three were HIV-negative and malaria antibody-positive, three were HIV-positive and malaria antibody-negative, and three were HIV-negative and malaria antibody-negative. While there were sample-to-sample variations, analysis of banding pattern (5 to > 22 proteins recognized) failed to reveal any noticeable difference in the antigen recognition patterns among the various groups of samples for antibodies against P. falciparum irrespective of HIV status. (Data not shown.)
To evaluate parasite growth inhibitory activity, various DRC plasma and normal human sera were diluted in the culture medium and tested in P. falciparum in vitro growth inhibition assays. One hundred L diluted plasma were added to each well containing 100 L of P. falciparum culture (1% of parasitemia and 5% of hematocrit) in triplicate wells. The plates were incubated for 48 hours at 37°C (5% C0 2 , 5% 0 2 and N 2 balance) in modular chambers. Smears were made from each well, fixed by methanol, stained by Giemsa solution (5%), and examined by light microscopy using oil immersion lens (100x). Total parasites were counted in 10-15 randomly selected fields representing a minimum of 1,000 erythrocytes and percent parasitemia determined for each test group. The mean parasitemia in the control wells (normal human sera) was 3.8% after 48 hours. Although various plasma from the DRC had strong P. falciparum growth inhibition activity (Table 1) , no significant correlation with HIV status was discernible ( Table 2 ). In growth inhibition assay, 11 malaria antibody-negative sera also gave significant reduction of parasite growth, suggesting that besides antibodies, other unknown immunologic mediators may affect parasite growth and contribute to productive immunity. For example, previous studies have demonstrated an anti-parasite role for gamma interferon and other proinflammatory and antiinflammatory cytokines.
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The pathogenesis of HIV infection is marked by the depletion of CD4 + T lymphocytes, an important component of CMI. HIV-associated immunosuppression may affect the prognosis of malaria by altering the immune response against P. falciparum, but such an interaction between malaria and HIV infection still remains highly debatable. Many clinical and in vitro studies have investigated such questions, and the results remain controversial. This issue led us to take advantage of samples from HIV-discordant and HIV-concordant couples living in malaria endemic areas and sharing a similar frequency of mosquito bites to approach this question. We found no significant correlation between HIV status and dysfunction of the immune response against malaria parasites. Our expectation was that altered immune responses during HIV infection will result in reduced antibodies against malaria antigens and thus negatively affecting the outcome of malaria during co-infection with HIV. In this cross-sectional study, we failed to observe any relationship between the various malaria parameters and HIV status. Knowledge of CD4 
